SIOG – International Society of Geriatric Oncology shared a post on LinkedIn:
“Sarcopenia and frailty get used almost interchangeably in oncology conversations. They shouldn’t be.
This session at SIOG 2026 unpacks both terms directly: how frailty gets misclassified in research and what that costs in clinical decision-making, why sarcopenia isn’t the same as low muscle mass, the prognostic value both carry for older adults with cancer, and what exercise and nutritional interventions are actually feasible outside a research setting. Speakers join from Spain, Ireland, and the United States.